Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients
 
  • Details

MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients

Journal
Modern Pathology
Journal Volume
33
Journal Issue
4
Pages
531-540
Date Issued
2020
Author(s)
HSIU-HAO CHANG  
Tseng Y.-F.
MENG-YAO LU  
YUNG-LI YANG  
SHU-WEI CHOU  
Lin D.-T.
Lin K.-H.
SHIANN-TANG JOU  
WEN-MING HSU  
YUNG-MING JENG  
DOI
10.1038/s41379-019-0410-x
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074898997&doi=10.1038%2fs41379-019-0410-x&partnerID=40&md5=163e1d7680d63a772d5b152b48240a96
https://scholars.lib.ntu.edu.tw/handle/123456789/526381
Abstract
The aim of this study was to investigate the prognostic role of MYCN RNA expression by quantitative RNA in situ hybridization and its association with MYCN amplification in neuroblastoma. MYCN RNA expression in 69 neuroblastoma tumors was evaluated by an ultrasensitive quantitative RNA in situ hybridization technique, RNAscope. The correlations between MYCN RNA expression, MYCN amplification, and other clinicopathologic variables of neuroblastoma were analyzed. High expression levels of MYCN RNA were detected 30 of 69 (43%) of neuroblastomas, mainly in those with undifferentiated or poorly differentiated histology. High expression of MYCN RNA was significantly associated with MYCN amplification (P < 0.001) and other adversely prognostic factors, including older age at diagnosis (>18 months, P = 0.017), advanced clinical stage (International Neuroblastoma Staging System stage 3, 4, P = 0.002), unfavorable International Neuroblastoma Pathology Classification tumor histology (P < 0.001), and high-risk Children’s Oncology Group risk group (P = 0.001). In Kaplan–Meier analysis, MYCN RNA levels determined by quantitative in situ hybridization were better than MYCN gene dosages determined by chromogenic in situ hybridization in discriminating good and poor prognostic groups of neuroblastoma patients. In multivariate analysis, we further confirmed that high expression of MYCN RNA was an independent adverse prognostic factor for event-free and overall survival. Furthermore, high expression of MYCN RNA predicted unfavorable survival outcomes for neuroblastoma patients with MYCN non-amplification or high-risk Children’s Oncology Group risk group. In conclusion, our study is the first report to show the application of MYCN RNA in situ hybridization in neuroblastoma and established that high expression of MYCN RNA could be a better biomarker than MYCN amplification for predicting poor prognosis of neuroblastoma patients. ? 2019, The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
SDGs

[SDGs]SDG3

Other Subjects
messenger RNA; MYCN protein, human; N Myc proto oncogene protein; RNA; tumor marker; Article; autologous bone marrow transplantation; cancer chemotherapy; cancer patient; cancer prognosis; cancer radiotherapy; child; event free survival; female; gene amplification; gene dosage; high risk population; human; human tissue; in situ hybridization; infant; major clinical study; male; mRNA expression level; multimodality cancer therapy; MYCN gene; neuroblastoma; oncogene; overall survival; priority journal; real time reverse transcription polymerase chain reaction; comparative study; gene amplification; gene dosage; gene expression regulation; genetic predisposition; genetics; in situ hybridization; mortality; neuroblastoma; pathology; predictive value; preschool child; prognosis; real time polymerase chain reaction; retrospective study; reverse transcription polymerase chain reaction; Biomarkers, Tumor; Child; Child, Preschool; Female; Gene Amplification; Gene Dosage; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; In Situ Hybridization; Infant; Male; N-Myc Proto-Oncogene Protein; Neuroblastoma; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm
Publisher
Springer Nature
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science